Krystal's manufacturing milestone moves it closer to commercial readiness

15 January 2019
krystal_large

US gene therapy company Krystal Biotech (Nasdaq: KRYS) has finished building its manufacturing facility close to its Pittsburgh headquarters.

The site will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for dystrophic epidermolysis bullosa (DEB), and will officially open early this year following completion of the first engineering run.

Krish Krishnan, chairman and chief executive officer of Krystal, which is developing topical and intradermal off-the-shelf treatments for rare dermatological diseases, said: “Our development of internal manufacturing capabilities bolsters our position for commercial readiness as we execute on our vision to bring our therapies to the patient communities in need.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology